logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
31/10/2025
According to AI Fast News, Dongwu Securities issued a research report on October 30th, giving Hemai Stock (688032.SH) a "buy" rating. The main reasons for the rating include: 1) the impact of the price war on shipments and profits; 2) the delay in the receipt of energy storage and high targets for all products next year; 3) the significant increase in expenses due to a decrease in revenue. (Daily Economic News)
Latest
2 m ago
Hong Kong stock market anomaly | China Railway Group (00390.HK) fell more than 4% in the afternoon, with a 14.97% year-on-year decrease in net profit in the first three quarters. The decline in third-quarter performance narrowed.
3 m ago
Lan Foan: Optimize the relationship between central and local finances and improve the system of fiscal transfer payments.
3 m ago
Lan Fo'an: Implement and improve the mechanism for the distribution and management of central government science and technology funds, and enhance the effectiveness of input in scientific and technological innovation.
4 m ago
Dongyang Guangyao (06887.HK) independently developed a new nucleic acid drug for hepatitis B that has been approved for clinical use in China.
4 m ago
National Development and Reform Commission: An additional 200 billion yuan special bond quota specifically for supporting investment and construction in some provinces.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.